Company intelligence / Profile preview

Marvel Biosciences

Calgary, Alberta, Canada

Ownership: Private
Development stage: Other

Overview

Alphanco Venture was a TSX Venture capital pool company that completed a qualifying transaction in 2021 by acquiring Marvel Biotechnology Inc., subsequently changing its name to Marvel Biosciences Corp, a life sciences company focused on discovery and development of small-molecule therapeutics for depression and other neurological conditions; its lead compound MB-204 (compound 1b) remains in pre-clinical development.[2][3][4][6][1]

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Marvel Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marvel Biosciences.

Explore the full profile